Body
In this week's PLoS Medicine, the Editors argue that drug companies should be held much more accountable for their human rights responsibilities to make medicines available and accessible to those in need. Despite decades of advocacy on the part of the access to medicines movement, and human rights guidelines developed in 2008 for pharmaceutical companies that make clear that their responsibilities go beyond stakeholder value to encompass human rights, there is inadequate accountability, say the Editors.
DURHAM, N.C. – The yellow monkeyflower, an unassuming little plant that lives as both a perennial on the foggy coasts of the Pacific Northwest and a dry-land annual hundreds of miles inland, harbors a significant clue about evolution.
You may not think of the fizz in soda as spicy, but your body does.
The carbon dioxide in fizzy drinks sets off the same pain sensors in the nasal cavity as mustard and horseradish, though at a lower intensity, according to new research from the University of Southern California.
"Carbonation evokes two distinct sensations. It makes things sour and it also makes them burn. We have all felt that noxious tingling sensation when soda goes down your throat too fast," said Emily Liman, senior author of a study published online in the Journal of Neuroscience.
Grand Rapids, Mich. (September 28, 2010) – New findings from Van Andel Research Institute (VARI) scientists could lead to environmentally-friendly sprays that help plants survive drought and other stresses in harsh environments to combat global food shortages. The study is a follow-up to findings published in Nature last year that were named among the top breakthroughs of 2009 by Science magazine.
DENVER — African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.
DENVER — Scientists may have discovered a way to diagnose bladder cancer at its earliest and, therefore, most treatable stages by measuring the presence or absence of microRNA using already available laboratory tests.
"Measuring expressions of microRNA in bodily fluid represents a very promising tool with widespread implications for screening," said Liana Adam, M.D., Ph.D., assistant professor in urology at The University of Texas MD Anderson Cancer Center.
DENVER — Targeting c-Met may be a promising personalized treatment method for approximately 45 percent of patients with hepatocellular carcinoma (HCC) who have c-Met-positive tumors, according to study results presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
HCC is the most common primary malignant tumor of the liver; c-Met is a receptor for hepatocyte growth factor that appears to drive liver cancer growth, invasion and metastasis.
Average C-reactive protein (CRP) values vary in diverse populations — possibly impacting how doctors estimate cardiovascular risk and determine statin treatment, according to a new study in Circulation: Cardiovascular Genetics, a journal of the American Heart Association.
DETROIT – The old saying, "never put anything smaller than your elbow in your ear," couldn't be truer for a patient who experienced vertigo and severe hearing loss after a cotton swab perforated her eardrum and damaged her inner ear.
But what makes this patient's case unique is that otolaryngologists at Henry Ford Hospital in Detroit were not only able to alleviate her vertigo with surgery, but restore her hearing – an extremely rare occurrence.
Washington, D.C. (September 28, 2010) -- A new disposable device based on advances in microfluidics may help identify advanced breast cancer patients who are candidates for therapy with the drug trastuzumab (Herceptin). The device is described in the American Institute of Physics' journal Biomicrofluidics.
DENVER — Patients with triple-negative breast cancer, one of the hardest subtypes to treat, may have a unique biomarker that would enable them to receive more targeted therapy, according to data presented at the Fourth AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development.
Triple-negative breast cancers are breast cancers that have tested negative for estrogen receptors, progesterone receptors and HER2. Because of this biology, these cancers do not respond to endocrine therapies or trastuzumab.
DENVER — Researchers in England say they have discovered a set of biomarkers that can distinguish prostate cancer from benign prostate disease and healthy tissue with 90 percent accuracy. This preliminary data, if validated in larger ongoing studies, could be developed into a serum protein test that reduces the number of unnecessary biopsies and identifies men who need treatment before symptoms begin.
DENVER — Using a novel aptamer-based proteomics array technology, researchers and collaborators have identified biomarkers and protein signatures that are hallmarks of cancer at an early stage for two of the most aggressive and deadly forms of cancer — pancreatic and mesothelioma.
This technology would enable better clinical diagnosis at an earlier stage and may provide insight into new therapeutic targets, said Rachel Ostroff, Ph.D., clinical research director of Somalogic Inc.
(Boston) - Researchers from Boston Medical Center (BMC) and Boston University School of Public Health (BUSPH) have found that individuals who do not speak English at home are less likely to receive colorectal cancer screenings (CRC) as compared to those who do speak English at home. The findings, which currently appear on-line in the Journal of General Internal Medicine, suggest that patient-provider language barriers play a role in health-care disparities, and that providers should promote the importance of CRC screening to non-English speaking patients.